We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Researchers from the Brookings Institution are calling for fresh incentives to improve manufacturing infrastructure and drug quality to reduce ongoing, persistent shortages of generic sterile injectables (GSIs). Read More
As the 118th Congress continues, FDAnews will track important pending legislation to keep you updated on regulations that could impact your business. Read More
Following a fiery social media post, Johnson & Johnson has agreed to grant licenses to Stop TB Partnership’s global drug facilities to middle and low income countries to produce generic versions of its Sirturo (bedaquiline), the first new drug to treat multi-drug resistant tuberculosis (MDR-TB) in 50 years. Read More
A revised report from the Institute for Clinical Evaluation and Research (ICER) has reiterated that two experimental gene therapies for sickle cell disease (SCD) would likely be cost-effective if priced at $2 million. Read More
Eli Lilly’s generic insulin Lispro can cost nearly four times as much as the company’s promised price of $25 per vial, according to a new report from Democratic Senators Elizabeth Warren (Mass.), Raphael Warnock (Ga.) and Richard Blumenthal (Conn). Read More
With COVID-19 vaccines moving to the open market postpandemic, their manufacturers should remember the support they received from the federal government when setting prices, said HHS Secretary Xavier Becerra in an open letter to COVID-19 vaccine manufacturers. Read More
The U.S. Chamber of Commerce and three other chambers have filed a motion for a preliminary injunction preventing implementation of the Drug Price Negotiation Program in the Inflation Reduction Act (IRA) because it violates the Fifth Amendment Due Process Clause. Read More
The FTC will continue its ongoing examination of the pharmacy benefit management (PBM) industry at an open meeting July 20 when it decides whether to issue a warning to PBMs to stop relying on older FTC advocacy materials that opposed mandatory PBM transparency and disclosure requirements. Read More
Over the past week, the FDA has issued draft guidances on inborn errors of metabolism, clinical trial postmarketing studies and human cellular and gene therapy products. Read More
It is not clear yet whether the reported cases are linked to the drugs, to the patients’ underlying conditions or other factors, the EMA stated. Read More
In an effort to improve adherence with postmarketing requirements (PMR), the FDA has laid out the circumstances under which noncompliance with PMRs is justified in a new draft guidance. Read More
Acknowledging the complexity of human cellular and gene therapy (CGT) products, the FDA has written a draft guidance intended to help manufacturers manage and report changes in products, based on a lifecycle approach, and how to assess the effect of manufacturing changes on product quality. Read More